Last reviewed · How we verify

High dose of Micardis®, once daily

Boehringer Ingelheim · FDA-approved active Small molecule Quality 5/100

High dose of Micardis®, once daily is a Small molecule drug developed by Boehringer Ingelheim. It is currently FDA-approved. Also known as: Telmisartan.

At a glance

Generic nameHigh dose of Micardis®, once daily
Also known asTelmisartan
SponsorBoehringer Ingelheim
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about High dose of Micardis®, once daily

What is High dose of Micardis®, once daily?

High dose of Micardis®, once daily is a Small molecule drug developed by Boehringer Ingelheim.

Who makes High dose of Micardis®, once daily?

High dose of Micardis®, once daily is developed and marketed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

Is High dose of Micardis®, once daily also known as anything else?

High dose of Micardis®, once daily is also known as Telmisartan.

What development phase is High dose of Micardis®, once daily in?

High dose of Micardis®, once daily is FDA-approved (marketed).

Related